Results 21 to 30 of about 30,146 (272)
Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
Hematology, 2022 Objectives Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival. While allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for myelofibrosis, the ...
Timothy Devos +4 more
doaj +1 more source
A key role for leukemia inhibitory factor in C26 cancer cachexia [PDF]
, 2015 Cachexia is an exacerbating event in many types of cancer that is strongly associated with a poor prognosis. We have identified cytokine, signaling, and transcription factors that are required for cachexia in the mouse C26 colon carcinoma model of cancer.
Jackman, Robert W. +2 more
core +1 more source
Trends in overall mortality among US veterans with primary myelofibrosis
BMC Cancer, 2023 Background Primary myelofibrosis [PMF] is a myeloproliferative neoplasm associated with reduced overall survival (OS). Management strategies for PMF have evolved over the last two decades, including approval of ruxolitinib as the first Janus kinase 1 ...
Tsewang Tashi +5 more
doaj +1 more source
Recent progress of JAK inhibitors for hematological disorders
Immunological Medicine, 2023 JAK inhibitors are important therapeutic options for hematological disorders, especially myeloproliferative neoplasms. Ruxolitinib, the first JAK inhibitor approved for clinical use, improves splenomegaly and ameliorates constitutional symptoms in both ...
Keita Kirito
doaj +1 more source
Alopecia areata: a multifactorial autoimmune condition [PDF]
, 2019 Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is clinically characterised by small patches of baldness on the scalp and/or around the body. It can later progress to total loss of scalp hair (Alopecia totalis) and/
Butcher, John P. +3 more
core +1 more source
Journal of Hematology & Oncology, 2017 Background Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor,
Srdan Verstovsek +13 more
doaj +1 more source
COVID-19 in a patient with SISTEMIC sclerosis: The role of ruxolitinib
European Journal of Inflammation, 2021 We describe the case of a 78-year-old Italian woman with COVID-19 affected by Systemic Sclerosis with pulmonary fibrosis treated with Ruxolitinib (Ruxolitinib was provided free of charge by Novartis International AG).
Claudio Ucciferri +4 more
doaj +1 more source
Клиническая онкогематология, 2021 Aim. To comparatively analyze myelofibrosis treatment outcomes with the use of ruxolitinib versus ruxolitinib with subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT) as well as to assess the efficacy of ruxolitinib in pre- and post-
Mariya Vladimirovna Barabanshchikova +11 more
doaj +1 more source
Haematologica, 2019 Ruxolitinib is the front-line non-palliative treatment for myelofibrosis (MF). However, a significant number of patients lose or present suboptimal response, are resistant or have unacceptable toxicity.
Alicia Arenas Cortés +11 more
doaj +1 more source
Pediatric Rheumatology Online Journal, 2021 Background This study aimed to analyze the effects of ruxolitinib on children with secondary hemophagocytic lymphohistiocytosis (HLH). Methods Eleven pediatric patients diagnosed with HLH and treated with ruxolitinib (ruxolitinib group: group R) between ...
Ying Chi +5 more
doaj +1 more source